Background
Methods
Data sources and literature search strategy
Inclusion and exclusion criteria
Quality of original studies
Data extraction
Data synthesis and statistical analysis
Quality of evidence
Results
Study selection
Study characteristics and quality
Study | Year | Country | Study design | Sample size | Male/ Female ratio | Mean age | Histology (clear cell%) | Survival analysis | Definition of hypertension | Type of analysis | TKIs | Quality Assessment (NOS Score = 9) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Rini (a) [10] | 2011 | the USA | R | 534 | 2.3 | 60.6 | 98% | PFS, OS | SBP ≥ 140 mmHg, DBP ≥ 90 mmHg | multivariate | SUN | 7 |
Szmit [12] | 2011 | Poland | R | 111 | 3.0 | 55.9 | 100% | PFS, OS | BP ≥ 140/90 mmHg | univariate | SUN | 9 |
Bono [17] | 2011 | Finland | R | 64 | 1.7 | 64 | 92% | PFS | BP > 150/100 mmHg OR blood pressure requiring intensifi cation of pre-existing anti-hypertensive medication. | multivariate | SUN | 7 |
Fujita [18] | 2012 | Japan | R | 41 | 2.7 | 64 | 100% | PFS | – | univariate | SUN | 7 |
Eechoute [19] | 2012 | Netherlands | R | 158 | 1.7 | 60 | 87% | PFS, OS | SBP > 140 mmHg, DBP > 90 mmHg, MAP > 110 mmHg | multivariate | SUN | 7 |
Rini (b) [13] | 2013 | the USA | R | 168 | 2.5 | 60 | – | PFS, OS | DBP ≥90 mmHg | multivariate | AXI | 7 |
Motzer (a) [20] | 2013 | the USA | P | 350 | 2.8 | 61 | 100% | PFS, OS | SBP > 140 mmHg, DBP > 90 mmHg | multivariate | AXI | 6 |
Motzer (b) [20] | 2013 | the USA | P | 336 | 2.5 | 61 | 100% | PFS, OS | SBP > 140 mmHg, DBP > 90 mmHg | multivariate | SOR | 6 |
Hong [21] | 2013 | China | R | 136 | 2.0 | 56 | 93% | OS | Hypertension class III/IV | multivariate | SUN | 7 |
Nakano [22] | 2013 | Japan | R | 36 | 3.5 | 65.8 | 61% | PFS | grade 1–3 (NCI-CTCAE, version 3.0) | multivariate | SOR | 7 |
Fujita [23] | 2014 | Japan | R | 44 | 2.7 | 63.5 | 95% | PFS | – | multivariate | SUN | 7 |
Eto [24] | 2014 | Japan | R | 64 | 2.2 | 63 | 97% | OS | DBP ≥90 mmHg | – | AXI | 7 |
Rini (c) [25] | 2015 | the USA | P | 203 | 2.0 | 61.9 | – | PFS | DBP change from baseline ≥10/15 mmHg | – | AXI | 7 |
Zhang (a) [26] | 2015 | China | R | 256 | 2.5 | 58 | 79% | OS | – | multivariate | SOR | 7 |
Kucharz [27] | 2015 | Poland | R | 28 | 2.1 | 65 | – | PFS | office SBP ≥140 and/or DBP ≥90 mmHg; home SBP ≥135 and/or DPB ≥85 mmHg; pre-existing medication-controlled arterial hypertension and required additional antihypertensive medication during treatment | multivariate | SUN | 7 |
Izzedine [28] | 2015 | France | R | 212 | 3.4 | 57.7 | 86% | PFS, OS | – | multivariate | SUN | 8 |
Donskov [29] | 2015 | the USA | R | 770 | 2.6 | 60 | 98% | PFS | SBP ≥ 140 mmHg | multivariate | SUN | 7 |
Zhang (b) [30] | 2016 | China | R | 134 | 2.4 | 59.8 | 77% | OS | – | multivariate | SOR | 7 |
Goldstein (a) [14] | 2016 | Australia | R | 479 | 2.2 | 59.5 | – | PFS, OS | MAP change from baseline>10 mmHg | univariate | PAZ | 9 |
Goldstein (b) [14] | 2016 | Australia | R | 506 | 2.6187 | 61 | – | PFS, OS | SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg | univariate | PAZ | 9 |
Goldstein (c) [14] | 2016 | Australia | R | 475 | 3.3394 | 60.9 | – | PFS, OS | SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg | univariate | SUN | 9 |
Cecere [31] | 2016 | Italy | R | 38 | 1.375 | 61 | 84.2% | OS | grade ≥ 3 (NCI-CTCAE, version 4.0) | multivariate | PAZ | 7 |
Miyake [32] | 2016 | Japan | R | 50 | 4.0000 | 64 | 80% | PFS | SBP ≥ 140 or DBP ≥ 90 mmHg | multivariate | SUN | 7 |
Fukuda [15] | 2016 | Japan | R | 62 | 2.4444 | 66 | 92% | PFS, OS | – | univariate | SUN | 7 |
Matias [33] | 2017 | France | P | 106 | 2.3125 | 54 | 90% | PFS, OS | grade ≥ 3 (NCI-CTCAE, version 4.0) | univariate | AXI | 7 |
Study | Selection (4 stars) | Comparability (2 stars) | Outcome (3 stars) | Total score | |||||
---|---|---|---|---|---|---|---|---|---|
Representativeness of the hypertensive cohort | Selection of the non-hypertensive cohort | Ascertainment of hypertension | Demonstration that outcome of interest was not present at start of study | Assessment of outcome | Was follow up long enough for outcomes to occur? | Adequacy of follow up of cohort | |||
Rini (a) | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Szmit | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
Bono | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Fujita | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Eechoute | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Rini (b) | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Motzer | – | ★ | ★ | ★ | – | ★ | ★ | ★ | 6 |
Hong | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Nakano | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Fujita | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Eto | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Rini (c) | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Zhang (a) | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Kucharz | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Izzedine | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 |
Donskov | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Zhang (b) | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Goldstein | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
Miyake | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Fukuda | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Matias | ★ | ★ | ★ | ★ | – | ★ | ★ | ★ | 7 |
Relationship between TKIs-induced hypertension and PFS or OS of mRCC patients
Meta-regression analysis
Subgroup | Meta-regression | Pooled HR of PFS | Heterogeneity | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. of studies | Coefficient | Standard error | T value | P value | Tau2 | Adjusted R2 | HR (95% CI) | P value | I2 | P value | |
Year | 20 | 0.060 | 0.228 | 0.26 | 0.795 | 0.182 | −8.86% | ||||
2011–2014 | 0.56 (0.40–0.77) | <0.001 | 83.00% | <0.001 | |||||||
2015–2017 | 0.61 (0.48–0.77) | <0.001 | 73.60% | <0.001 | |||||||
Sample size | 20 | 0.507 | 0.197 | 2.57 | 0.019 | 0.122 | 27.34% | ||||
<200 | 0.43 (0.30–0.61) | <0.001 | 72.10% | <0.001 | |||||||
≥200 | 0.73 (0.60–0.89) | 0.002 | 75% | <0.001 | |||||||
Gender (male/female ratio) | 20 | −0.117 | 0.228 | −0.51 | 0.614 | 0.177 | −5.64% | ||||
<2.5 | 0.66 (0.53–0.82) | <0.001 | 54.50% | 0.025 | |||||||
≥2.5 | 0.55 (0.40–0.74) | <0.001 | 84.70% | <0.001 | |||||||
Mean age | 20 | 0.320 | 0.264 | 2.21 | 0.241 | 0.156 | 6.69% | ||||
<60 | 0.44 (0.23–0.86) | 0.015 | 89.40% | <0.001 | |||||||
≥60 | 0.64 (0.53–0.78) | <0.001 | 69.70% | <0.001 | |||||||
Country | 20 | 0.168 | 0.301 | 0.56 | 0.584 | 0.173 | −3.31% | ||||
the USA, Europe | 0.60 (0.49–0.74) | <0.001 | 81.40% | <0.001 | |||||||
Asia | 0.51 (0.31–0.83) | 0.006 | 39.50% | 0.158 | |||||||
ECOG PS (grade 0%) | 20 | 0.036 | 0.133 | 0.27 | 0.79 | 0.182 | −8.59% | ||||
<0.5 | 0.35 (0.14–0.89) | 0.028 | 87.20% | <0.001 | |||||||
≥0.5 | 0.64 (0.52–0.79) | <0.001 | 71.90% | <0.001 | |||||||
MSKCC score (favorable%) | 20 | 0.231 | 0.111 | 2.08 | 0.052 | 0.123 | 26.74% | ||||
<0.25 | 0.43 (0.21–0.87) | 0.019 | 76% | 0.002 | |||||||
≥0.25 | 0.86 (0.73–1.02) | 0.076 | 40.30% | 0.137 | |||||||
Histology (clear cell%) | 20 | −0.139 | 0.126 | −1.11 | 0.283 | 0.166 | 1.11% | ||||
<0.9 | 0.53 (0.39–0.71) | <0.001 | 29.30% | 0.226 | |||||||
≥0.9 | 0.51 (0.33–0.79) | 0.002 | 87.90% | <0.001 | |||||||
Prior nephrectomy (%) | 20 | −0.162 | 0.129 | −1.25 | 0.226 | 0.166 | 1.16% | ||||
<0.9 | 0.52 (0.40–0.67) | 0.296 | 17.50% | <0.001 | |||||||
≥0.9 | 0.52 (0.33–0.81) | <0.001 | 89.30% | 0.005 | |||||||
No. of disease sites (1%) | 20 | −0.253 | 0.139 | −1.81 | 0.086 | 0.144 | 13.81% | ||||
<0.2 | 0.41 (0.28–0.60) | <0.001 | 62.40% | 0.047 | |||||||
≥0.2 | 0.52 (0.37–0.74) | <0.001 | 0 | 0.594 | |||||||
Type of analysis | 20 | −0.030 | 0.231 | −0.13 | 0.898 | 0.182 | −8.91% | ||||
Univariate | 0.59 (0.42–0.82) | 0.002 | 82.70% | <0.001 | |||||||
Multivariate | 0.58 (0.46–0.75) | <0.001 | 74.50% | <0.001 | |||||||
Study design | 20 | 0.343 | 0.257 | 1.34 | 0.198 | 0.157 | 6.32% | ||||
Retrospective | 0.54 (0.44–0.67) | <0.001 | 74.90% | <0.001 | |||||||
Prospective | 0.77 (0.53–1.12) | 0.175 | 76.20% | 0.006 | |||||||
Type of TKIs | 20 | −0.073 | 0.114 | −0.64 | 0.942 | 0.178 | −10.49% | ||||
Axitinib | 0.70 (0.48–1.03) | 0.07 | 80.90% | 0.001 | |||||||
Sorafenib | 0.86 (0.65–1.13) | 0.277 | 0 | 0.339 | |||||||
Sunitinib | 0.47 (0.34–0.64) | <0.001 | 77.90% | <0.001 | |||||||
Pazopanib | 0.79 (0.66–0.94) | 0.010 | 0 | 1.000 |
Subgroup analysis
Sensitivity analysis
Publication bias
Evaluation of the quality of evidence according to GRADE system
Quality assessment | No. of patients | Hazard Ratios (95% CI) | Quality | Importance | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TKI-induced hypertension | Control | |||
Progression-free survival (follow-up median 5.6–43.2 years; measured with: follow-up) | |||||||||||
20 | observational studies | no serious risk of bias | serious1 | no serious indirectness | no serious imprecision | reporting bias2 | 3021 | 1327 | 0.59 (0.48–0.71) | Very low | Critical |
Overall survival (follow-up median 5.2–61.8 months; measured with: follow-up) | |||||||||||
17 | observational studies | no serious risk of bias | serious1 | no serious indirectness | no serious imprecision | reporting bias3 | 2313 | 1804 | 0.57 (0.45–0.70) | Very low | Critical |